Project Details
Description
A Phase 3 Randomized, Open-label Study of OP- 1250 Monotherapy vs Standard of Care for the Treatment of Subjects with HR+/HER2- Locally Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy study
| Status | Active |
|---|---|
| Effective start/end date | 3/8/23 → 6/30/27 |
Funding
- OLEMA PHARMACEUTICALS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.